ArticleBMJ public health2025
Impact of type 2 diabetes on the risk of cardiovascular disease and cardiovascular mortality in patients with non-alcoholic fatty liver disease: a nationwide population-based study.
Article in BMJ public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association of the fibrosis-4 index with prevalent diabetes among adults: a cross-sectional analysis of NHANES 2003-2018 and a Chinese hospital-based health examination population.Frontiers in endocrinology · 2026Article
- Survival machine learning models for predicting all-cause and case-specific mortality risk in metabolic dysfunction-associated fatty liver disease patients.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: A complex bidirectional association between type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD) has been linked to unfavourable metabolic profile and an increasing risk of cardiovascular disease (CVD). This study aimed to investigate long-term CVD outcomes in patients with NAFLD according to glycaemic status using a nationwide cohort of Korean adults. Methods: This longitudinal study included 1 057 775 patients with NAFLD, who had participated in the national health screening in 2009 from baseline to the date of diagnosis of myocardial infarction (MI), stroke and cardiovascular (CV) death or up to 2020 during a follow-up period of 11.3 years. The baseline glycaemic status was divided into three categories (normal fasting glucose (NFG), impaired fasting glucose (IFG) and T2D). Results: A total of 26 491 cases of MI, 55 791 cases of stroke and 11 147 cases of CV death were identified. After adjusting for possible covariates, participants with T2D had a higher risk of CVD, with HRs of 1.39 (95% CI 1.35 to 1.44) for MI, 1.39 (95% CI 1.36 to 1.42) for stroke and 1.46 (95% CI 1.39 to 1.52) for CV death, compared with those with NFG. The IFG group did not exhibit a significant increase in the risk of MI, stroke and CV death compared with the NFG group. The increased risk of CVD attributable to T2D was more profound among individuals with fewer conventional risk factors, including younger age, not obese and the absence of hypertension. Conclusion: T2D is associated with an increased risk of CVD and CV mortality in patients with NAFLD. These results suggest that the identification of T2D in individuals with NAFLD may help in the early prediction of future progression of CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.